go back

Brexucabtagene Autoleucel (Tecartus)

Illinois rates for HCPCS C9073

Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

Facilitymedian $1,905,461 · 10th–90th $676,083$5,370,3180%10%10th90th$1,905,461Professionalmedian $446,684 · 10th–90th $446,684$446,6840%50%100%$446,684$500.0K$1.0M$2.0M$5.0M

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Small sample; interpret with caution. Need provider-level prices? Contact us.

Insurance Carrier
BCBS
Setting
Facility
Modifier
Global
Typical Low
$676,082.98
Median
$1,905,460.72
Typical High
$5,370,317.96
United
Setting
Professional
Modifier
Global
Typical Low
$446,683.59
Median
$446,683.59
Typical High
$446,683.59